Glucocorticoid-Induced Osteoporosis (GIOP)

Area of Science:

• Endocrinology
• Rheumatology
• Pulmonology

Background:

• Glucocorticoid use is increasing for rheumatologic and respiratory diseases due to rapid benefits.
• This widespread use is linked to a rise in osteoporosis and fragility fractures.
• Judicious glucocorticoid administration requires attention to dose, route, and supportive factors.

Purpose of the Study:

• To highlight the risks of glucocorticoid-induced osteoporosis and fragility fractures.
• To emphasize the need for careful management strategies in clinical practice.
• To discuss therapeutic interventions for preventing fractures in patients on glucocorticoids.

Main Methods:

• Review of current literature on glucocorticoid use and bone health.
• Analysis of WHO risk stratification guidelines for osteoporosis.
• Discussion of pharmacological interventions including bisphosphonates, teriparatide, and denosumab.

Main Results:

• Glucocorticoids significantly increase the risk of osteoporosis and subsequent fragility fractures.
• Effective prevention strategies involve optimizing glucocorticoid therapy and implementing bone-protective measures.
• Therapeutic options like bisphosphonates, teriparatide, and denosumab are crucial for managing fracture risk.

Conclusions:

• Optimizing glucocorticoid therapy and understanding its adverse effects are essential.
• Proactive management with bone-protective agents is necessary to mitigate fracture risk.
• Further research into glucocorticoid metabolism and tailored treatment strategies is warranted.